| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.081 | 0.01 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | -0.073 | 0.01 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.01 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.13 | 0.01 |